X
[{"orgOrder":0,"company":"NaviFUS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NaviFUS Launches Clinical Trial of a Combination FUS-Bevacizumab Therapy in rGBM Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"TAIWAN","productType":"Large molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"NaviFUS"},{"orgOrder":0,"company":"NaviFUS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NaviFUS Highlights Clinical Trial Data and Device Capabilities at Virtual International Focused Ultrasound Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"TAIWAN","productType":"Large molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"NaviFUS"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
Notable highlights from NaviFUS at the conference include its Epilepsy neuromodulation clinical trial that just finished its safety phase, preliminary progress from its FUS combined with Avastin in rGBM patients clinical trial and other trials.
Lead Product(s):
Bevacizumab
Therapeutic Area: Oncology
Product Name: Avastin
Highest Development Status: Undisclosed
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 24, 2020
Details:
NaviFUS System plus bevacizumab therapy open the blood-brain barrier (BBB) and enhance bevacizumab's efficacy in patients with recurrent glioblastoma (rGBM).
Lead Product(s):
Bevacizumab
Therapeutic Area: Oncology
Product Name: Avastin
Highest Development Status: Undisclosed
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 11, 2020